Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5519-5528

  Braun, Michael S ^a   Richman, Susan D ^a   Thompson, Lindsay ^a   Daly, Catherine L ^a   Meade, Angela M ^a   Adlard, Julian W ^a   Allan, James M ^a   Parmar, Mahesh K B ^a   Quirke, Philip ^a   Seymour, Matthew T ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; LOPERAMIDE; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PROTEIN MLH1; THYMIDYLATE SYNTHASE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; GLUTATHIONE TRANSFERASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLATINUM COMPLEX; TUMOR MARKER;

ABCB 1 GENE; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASSOCIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DYPD GENE; ERCC 2 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC MARKER; GENOTYPE; GSTP 1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MLH 1 GENE; MONOTHERAPY; MTHFR GENE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXICOGENETICS; TREATMENT OUTCOME; TYMS GENE; UGT 1A1 GENE; XRCC 1 GENE; CANCER INVASION; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; SURVIVAL; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GLUTATHIONE TRANSFERASE; HUMANS; LEUCOVORIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROBABILITY; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 73949096486     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6283     Document Type: Article

References (36)

1. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/ leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
2. Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370: 143-152, 2007
3. Braun MS, Richman SD, Quirke P, et al: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 26:2690-2698, 2008
4. Cheeseman SL, Joel SP, Chester JD, et al: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87:393-399, 2002
5. Leonard P, Seymour MT, James R, et al: Phase 2 study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87:1216-1220, 2002
6. Marsh S, Mallon MA, Goodfellow P, et al: Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 6:873-877, 2005
7. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation. Int J Cancer 101:253-258, 2002
8. Lecomte T, Ferraz J-M, Zinzindohoúe F, et al: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880-5888, 2004
9. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65-70, 2001
10. Ulrich CM, Yasui Y, Storb R, et al: Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C667T polymorphism. Blood 98:231-234, 2001
11. Cohen V, Panet-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611-1615, 2003
12. Chiusolo P, Reddiconto G, Casorelli I, et al: Preponderance of methylenetetrahydrofolate reductase C667T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13:1915-1918, 2002
13. Ito E, Yanagisawa Y, Iwahashi Y, et al: A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1. Biochem Biophys Res Commun 256:488-494, 1999
14. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
15. Sai K, Kaniwa N, Itoda M, et al: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13:741-757, 2003
16. Stoehlmacher J, Ghaderi V, Iobal S, et al: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075-3079, 2001
17. Park SY, Lam W, Cheng YC: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62:459-465, 2002
18. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J Natl Cancer Inst 94:936-942, 2002
19. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354, 2004
20. Ayres KL, Balding DJ: Measuring gametic disequilibrium from multilocus data. Genetics 157: 413-423, 2001
21. Børresen AL, Møller P, Berg K: Linkage dis-equilibrium analyses and restriction mapping of four RFLPs at the proa2(1) collagen locus: Lack of correlation between linkage disequilibrium and physical distance. Hum Genet 78:216-221, 1988
22. Plo I, Liao ZY, Barceló JM, et al: Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase 1-mediated DNA lesions. DNA Repair (Amst) 2:1087-1100, 2003
23. Goto S, Kamada K, Soh Y, et al: Significance of nuclear glutathione S-transferase P1 in resistance to anti-cancer drugs. Jpn J Cancer Res 93:1047-1056, 2002
24. Kweekel DM, Koopman M, Antonini NF, et al: GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: A study of the Dutch Colorectal Cancer Group. Br J Cancer 99:1316-1321, 2008
25. McLeod HL, Sargent DJ, Marsh S, et al: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer: Results from an intergroup trial. Proc Am Soc Clin Oncol 22:253a, 2003 (abstr 1013)
26. Mattison LK, Fourie J, Hirao Y, et al: The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: Pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 12:549-555, 2006
27. Gagné JF, Montminy V, Belanger P, et al: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617, 2002
28. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000
29. Rahman A: Considerations for integration of CDRH and CDER regulations-A case study: Irinotecan and UGT1A1. http://www.fda.gov/Cder/Offices/ OODP/presentation/rahman.pdf
30. Rouits E, Boisdron-Celle M, Dumont A, et al: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159, 2004
31. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
32. van Cutsem E, Labianca R, Hossfeld D, et al: Randomized phase 3 trial comparing infused irinotecan/ 5-fluorouracil/folinic acid versus 5-FU/FA in stage III colon cancer patients. (PETACC 3). J Clin Oncol 23:3s, 2005 (suppl; abstr LBA8)
33. Roth AD, Yan P, Dietrich D, et al: Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3 - EORTC 40993 - SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II- III colon cancer (COC) patients. J Clin Oncol 26:187s, 2008 (suppl; abstr 4036)
34. McLeod HL, Parodi L, Sargent DJ, et al: UGT1A1*28 toxicity and outcome in advanced colorectal cancer: Results from the trial N9741. J Clin Oncol 24:151s, 2006 (suppl; abstr 3520)
35. Shen R, Fan JB, Campbell D, et al: High-throughput SNP genotyping on universal bead arrays. Mutat Res 573:70-82, 2005
36. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumour MARKer prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184, 2005